Many inhibitors also have off-target effects, which become more pronounced at high concentrations
24 For further information on the decision to fund these medicines, see: People at high risk of cardiovascular and renal complications will benefit Several large randomised controlled trials (RCTs) have shown that treatment with a SGLT-2 inhibitor or GLP-1 receptor agonist provides significant cardiovascular benefit to people with type 2 diabetes
These medications slow gastric emptying, which helps regulate digestion and fosters a healthier gut environment
The system accounts for real-life variability
Patients with complex medical histories, psychiatric conditions, sleep disorders, cardiovascular concerns, autoimmune conditions, pregnancy considerations, or multiple medications should be especially cautious